NovAccess Global IncOTCQB:XSNX
- LAST PRICE0.0726
- TODAY'S CHANGE (%)-0.0454 (-38.4746%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close0.0770 / 0.1180
- Day Range
- 52 Week Range
- Volume5,432
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | XSNX |
|---|---|---|
| 10:44 ET | 101 | 0.0725 |
| 10:46 ET | 187 | 0.114 |
| 03:12 ET | 500 | 0.0726 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
NovAccess Global Inc | 2.5M | -0.4x | --- |
GlobeStar Therapeutics Corp | 2.7M | -0.3x | --- |
Salarius Pharmaceuticals Inc | 2.8M | -0.1x | --- |
Manhattan Scientifics Inc | 2.5M | -1.8x | --- |
Scopus Biopharma Inc | 2.8M | -0.1x | --- |
Ampio Pharmaceuticals Inc | 2.8M | -0.2x | --- |
Company Information
NovAccess Global Inc. is a biopharmaceutical company. The Company is engaged in developing immunotherapies to treat brain tumor patients in the United States. It specializes in research related to utilizing a patient's own immune system to attack the cancer. The Company's technology is designed to combine a dendritic cell-based immunotherapeutic approach with a combination of Toll-like receptor (TLR) adjuvants, TLR-AD1, to help promote an enhanced immune response against the patient's tumor. TLR-AD1 is a vaccine immunotherapy for the treatment of aggressive brain cancers, including glioblastoma and other high-grade gliomas. Its platform technology focuses on enhancing the patient's immune cells to fight their cancer by utilizing the antigens specific to the patient's tumor. It owns a cancer vaccine, which is a medication that stimulates or restores the immune system's ability to fight existing cancer by strengthening the body's natural defenses against the cancer cells.
Contact Information
- Headquarters
- 8584 E. WASHINGTON STREET, NO. 127CHAGRIN FALLS, OH, United States 44023
- Phone
- 213-642-9268
- Fax
- 949-266-5823
Executives
- Chairman of the Board
- Daniel Martin
- Chief Executive Officer
- Dwain Moris - Irvin
- Fractional Chief Financial Officer
- Neil Laird
- Independent Director
- Jason Anderson
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.5M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 21.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.48 |
EPS | $-0.17 |
Book Value | $-0.25 |
P/E Ratio | -0.4x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
